SCHEMBL24253821

SCHEMBL24253821

CSc1nncc(C2CCCC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 4/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
C1S P09871 1/20 0.33
MEN1 O00255 2/20 0.33
CYP3A4 P08684 2/20 0.33
KMT2A Q03164 2/20 0.33
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
HTR2A P28223 1/20 0.31
HTR7 P34969 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
TDP1 Q9NUW8 2/20 0.31
PDGFRB P09619 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30488533 0.93 ALDH1A1 (0.45) ALDH1A1L3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL11268817 0.93 ALDH1A1 (0.45) ALDH1A1L3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL18508459 0.74 L3MBTL1 (0.37) L3MBTL1HTR1ADRD2HTR2AHTR7
SCHEMBL20402756 0.74 L3MBTL1 (0.37) L3MBTL1HTR1ADRD2HTR2AHTR7
SCHEMBL11631291 0.72 ALDH1A1 (0.63) ALDH1A1L3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL7382850 0.71 LMNA (0.39) ALDH1A1L3MBTL1GAAMAPTHTT
SCHEMBL11270464 0.71 ALDH1A1 (0.40) ALDH1A1L3MBTL1CYP1A2CYP2C9CYP2C19
SCHEMBL20402747 0.70 HRH4 (0.47) L3MBTL1HRH4
SCHEMBL21133394 0.70 HRH4 (0.47) L3MBTL1HRH4
SCHEMBL24087860 0.70 MIF (0.38) L3MBTL1HTTSMN1; SMN2KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 ALDH1A1 323/4885L3MBTL1 4878/4885CYP1A2 85/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 ALDH1A1 323/4885L3MBTL1 4878/4885CYP1A2 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.